- Licensing deal gives iOnctura exclusive global development rights to novel TGFβ pathway inhibitor IOA-359
- Pipeline expansion builds on iOnctura’s strategy of targeting multiple cancer survival pathways with a single drug; in this case targeting therapy resistance and immune evasion pathways in addition to IOA-359’s direct effects on the tumor
- Grant will accelerate iOnctura’s preclinical investigation of this small molecule inhibitor in cancer
Geneva, Switzerland and Amsterdam, The Netherlands, 3 May 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces it has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline. The Company also announces it has, in collaboration with the University of Twente (UT), been awarded a grant from Health Holland and KWF (Dutch Cancer Society), reflecting the potential of IOA-359.